undamentalytics Newsletter
Sign in

Opus Genetics, Inc. (IRD) stock

Add to watchlist

Add holding +

NASDAQ: IRD Nasdaq Biotechnology Next results ~November 11, 2026

D Fundamentals grade

Opus Genetics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: every model's value for Opus Genetics, Inc. is far from the share price, which usually points to a data problem (a merger, a share-count change, a one-off) rather than a bargain or a bubble.

Price vs value

Under review: free cash flow after stock pay is not positive. We'll show the comparison once resolved.

Opus Genetics, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 7 selling2 purchases and 23 sales by directors and officers, last 12 monthsInsider trades
  • Funds73 adding, 28 cuttingOf 24 active managers that changed their stake, 16 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Opus Genetics files

Where Opus Genetics stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $10m, down 36.1% on a year earlier, a steeper fall than the 12.2% decline a quarter earlier. Free-cash-flow margin fell to -413.1% from -206.7% a year earlier. Operating margin narrowed to -513.5% from -420.7%. The diluted share count is up 127.5% on a year earlier, which dilutes existing holders. Against its peers on growth, profitability, cash generation and balance sheet, it grades D. It passes 2 of our 5 financial-health checks.

Our model value for Opus Genetics is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 6, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Opus Genetics, Inc.'s trailing-twelve-month revenue fell 36.1% year on year, with a free-cash-flow margin of -413.1%. Where it stands out: days sales outstanding of 39 days ranks 17 of 100 biotechnology companies we cover. Where it lags: change in share count of 127.5% ranks 153 of 156 biotechnology companies we cover.

Current signal Balance sheet growing far ahead of sales: Total assets grew 140% year over year while revenue fell 36% — the balance sheet is expanding 177 points faster than the business it supports.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Net cash. Cash exceeds long-term debt by $0.1bn.

Things to watch

  • Revenue shrinking. Revenue fell 36.1% over the last 12 months.
  • Growth slowing. The growth rate is 23.9 points lower than a quarter earlier.
  • Loss-making. Operating margin is -513.5%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 92.8 points on a year ago.
  • Burning cash. Free cash flow was -413.1% of revenue over the last 12 months.
  • Heavy stock-based pay. Stock pay equals 45.3% of revenue, against a median of 19.2% for biotechnology companies we cover: a real cost that cash-flow figures leave out.

Latest results: FY2026 Q2

Filed August 6, 2026
Earnings per share
-$0.08 against an average estimate of -$0.16: beat by 49.3%
Revenue
$1m, down 73.8% on a year earlier
Share reaction
-3.2% in the first session after the results on August 6, 2026, against +0.5% for the S&P 500
Next report
November 11, 2026; average EPS estimate -$0.15

Opus Genetics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+0.8%
  • 1 week+11.4%
  • 1 month-19.2%
  • This year+84.1%
  • 1 year+60.9%
  • 5 years-10.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$9.9M
Operating margin
-513.5%
Net margin
-1091.8%
EPS (TTM, diluted)
$-1.23

Growth

Revenue growth
−36.1%
Change in growth rate
−23.9 pts
Share count change
+127.5%

Cash

Free cash flow (TTM)
-$40.7M
FCF margin
-413.1%
Stock pay % of revenue
45.3%

Earnings

Last results
August 6, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Announcement
  3. Insider trade
  4. Announcement
  5. Announcement
  6. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Opus Genetics, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: free cash flow after stock pay is not positive.

The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.

Valuation models

We value Opus Genetics, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.7%: the 10-year Treasury yield (4.9%) plus a beta of 1.05 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.5 ~$0.5–$0.5 Left out: out of range vs price (0.13x)
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: This model is withheld pending its input or assumption review.
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: This model is withheld pending its input or assumption review.
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: This model is withheld pending its input or assumption review.
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$0.5 ~$0.5–$2.0 Left out: out of range vs price (0.14x)
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. — Does not apply: This model is withheld pending its input or assumption review.
Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. — Combined value withheld. Review the individual models and their assumptions.

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Opus Genetics, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 2019202020212022202320242025Now
Share price$7.64$6.49$3.73$3.53$3.01$1.19$2.01$3.70
Market value$22m$30m$55m$73m$65m$32m$125m$324m
+ Net debt (− = net cash)$3m−$16m−$24m−$43m−$51m−$30m−$44m−$54m
Enterprise value$25m$14m$31m$30m$14m$1m$81m$270m
Multiples
Price / sales 7.2x—94.1x1.8x3.4x2.9x8.8x32.8x
Price / earnings ———4.1x————
Price / free cash flow ———5.1x————
EV / EBITDA ———1.6x————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

10 /100

Weak moat

How hard Opus Genetics's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -80.3% of total assets over 10 years.

  • Durability 10 / 20

    Operating margin has been a median -280.2%; its worst year was -4079.3%.

  • Cash conversion 2 / 20

    Free cash flow was positive in 1 of 6 years, at a median -163.9% of revenue.

  • Discipline 0 / 20

    The diluted share count rose 3373.9% over five years; stock-based pay has been a median 20.3% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (15 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open. Analysts expect revenue of $2m and EPS of −$0.15 (range −$0.21 to −$0.09) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$0.94 −17% $14m −3%
Next −$0.71 +24% $14m −1%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −6.4% on 90 days ago. In the last 30 days, 1 analyst raised Opus Genetics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Opus Genetics, Inc., last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.00 Current fiscal year, 60 days ago: −$0.92 Current fiscal year, 30 days ago: −$0.94 Current fiscal year, 7 days ago: −$0.94 Current fiscal year, Now: −$0.94 −$0.94 Next fiscal year, 90 days ago: −$0.76 Next fiscal year, 60 days ago: −$0.71 Next fiscal year, 30 days ago: −$0.71 Next fiscal year, 7 days ago: −$0.71 Next fiscal year, Now: −$0.71 −$0.71

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.00−$0.76
60 days ago −$0.92−$0.71
30 days ago −$0.94−$0.71
7 days ago −$0.94−$0.71
Now −$0.94−$0.71

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.16 −$0.08 +49.3%
Mar 2026 −$0.14 −$0.75 −448.8%
Dec 2025 −$0.10 −$0.21 −110.0%
Sept 2025 −$0.13 −$0.25 −92.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 6, 2026

No numeric guidance in Opus Genetics, Inc.'s latest earnings release (filed August 6, 2026). Some companies give their outlook only on the earnings call.

Analyst recommendations

18 analysts, Oct 2026
Buy18100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202631518
  2. Sep 202631518
  3. Aug 202631619
  4. Jul 202631619

Counts of recommendations published by analysts covering Opus Genetics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
16.9%
of tradable shares
Days to cover
6.66
at average volume
Short interest, 1 month
+6%
to October 15, 2026
Held by institutions
69%
of shares
Held by insiders
12.2%
of shares
Employees
27
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
IRD−43%−5%−15%−61%+69%+84%
Industry peers (median)−35%−57%−18%−28%−5%−27%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
IRD33%42%33%33%42%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
IRD−75%−59%−59%−75%−51%−49%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from April 10, 2017 to April 10, 2025. Getting back needed a 45196% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$1.74 – $6.07
From 52-week high
−39.0%
vs 50-day average
−17.1%
vs 200-day average
−11.7%
Volatility (1 year)
81%
Beta vs S&P 500
1.12

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±8.6%
After a week
3 up, 9 down
typical move ±9.6%
After a month
5 up, 7 down
typical move ±18.5%
Results releasedNext dayS&P 500 next day5 days21 days
August 6, 2026 −3.2% +0.5% −1.6% +23.5%
May 12, 2026 −1.8% +0.4% −16.8% −23.6%
March 10, 2026 +5.0% −0.3% +0.6% +15.3%
February 19, 2026 −9.6% +0.5% −4.3% +17.1%
November 12, 2025 −6.1% −1.6% −5.6% +19.8%
August 13, 2025 +6.3% +0.4% +4.5% +24.3%
May 15, 2025 +7.4% +1.1% +6.3% −1.1%
March 31, 2025 −9.9% +1.0% −15.8% −5.9%
March 20, 2025 +9.6% −0.3% −13.9% −35.7%
November 12, 2024 −7.7% −0.3% −24.8% −5.1%
October 22, 2024 −12.0% −1.0% 0.0% −26.3%
August 13, 2024 −24.7% +2.0% −20.5% −24.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Opus Genetics, Inc. in five measures

Fundamentals grade D
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Opus Genetics, Inc.
$0 $20M $40M $60M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $57.2M Revenue (TTM), FY23 Q4: $19M Revenue (TTM), FY24 Q1: $19M Revenue (TTM), FY24 Q2: $16.4M Revenue (TTM), FY24 Q3: $8.4M Revenue (TTM), FY24 Q4: $11M Revenue (TTM), FY25 Q1: $13.7M Revenue (TTM), FY25 Q2: $15.4M Revenue (TTM), FY25 Q3: $14.6M Revenue (TTM), FY25 Q4: $14.2M Revenue (TTM), FY26 Q1: $12M Revenue (TTM), FY26 Q2: $9.9M $9.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $57.2M
FY23 Q4 $19M
FY24 Q1 $19M
FY24 Q2 $16.4M
FY24 Q3 $8.4M
FY24 Q4 $11M
FY25 Q1 $13.7M
FY25 Q2 $15.4M
FY25 Q3 $14.6M
FY25 Q4 $14.2M
FY26 Q1 $12M
FY26 Q2 $9.9M
Revenue growth, TTM YoY Opus Genetics, Inc.
-5000% 0% 5000% 10000% FY23 Q2 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q2: 9158.3% Revenue growth, TTM YoY, FY23 Q4: -52.2% Revenue growth, TTM YoY, FY24 Q1: -54.3% Revenue growth, TTM YoY, FY24 Q2: -63.7% Revenue growth, TTM YoY, FY24 Q3: -85.3% Revenue growth, TTM YoY, FY24 Q4: -42.3% Revenue growth, TTM YoY, FY25 Q1: -28.2% Revenue growth, TTM YoY, FY25 Q2: -6.2% Revenue growth, TTM YoY, FY25 Q3: 74.6% Revenue growth, TTM YoY, FY25 Q4: 29.1% Revenue growth, TTM YoY, FY26 Q1: -12.2% Revenue growth, TTM YoY, FY26 Q2: -36.1% -36.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q2 9158.3%
FY23 Q4 -52.2%
FY24 Q1 -54.3%
FY24 Q2 -63.7%
FY24 Q3 -85.3%
FY24 Q4 -42.3%
FY25 Q1 -28.2%
FY25 Q2 -6.2%
FY25 Q3 74.6%
FY25 Q4 29.1%
FY26 Q1 -12.2%
FY26 Q2 -36.1%
Operating margin (TTM) Opus Genetics, Inc.
-600% -400% -200% 0% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: 50.8% Operating margin (TTM), FY23 Q4: -55.5% Operating margin (TTM), FY24 Q1: -63.9% Operating margin (TTM), FY24 Q2: -91.7% Operating margin (TTM), FY24 Q3: -351.7% Operating margin (TTM), FY24 Q4: -564.7% Operating margin (TTM), FY25 Q1: -471.0% Operating margin (TTM), FY25 Q2: -420.7% Operating margin (TTM), FY25 Q3: -445.4% Operating margin (TTM), FY25 Q4: -271.9% Operating margin (TTM), FY26 Q1: -359.1% Operating margin (TTM), FY26 Q2: -513.5% -513.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 50.8%
FY23 Q4 -55.5%
FY24 Q1 -63.9%
FY24 Q2 -91.7%
FY24 Q3 -351.7%
FY24 Q4 -564.7%
FY25 Q1 -471.0%
FY25 Q2 -420.7%
FY25 Q3 -445.4%
FY25 Q4 -271.9%
FY26 Q1 -359.1%
FY26 Q2 -513.5%
FCF margin (TTM) Opus Genetics, Inc.
-600% -400% -200% 0% 200% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: 40.4% FCF margin (TTM), FY23 Q4: -5.9% FCF margin (TTM), FY24 Q1: -16.8% FCF margin (TTM), FY24 Q2: -69.7% FCF margin (TTM), FY24 Q3: -162.2% FCF margin (TTM), FY24 Q4: -232.8% FCF margin (TTM), FY25 Q1: -211.5% FCF margin (TTM), FY25 Q2: -206.7% FCF margin (TTM), FY25 Q3: -224.9% FCF margin (TTM), FY25 Q4: -248.7% FCF margin (TTM), FY26 Q1: -325.8% FCF margin (TTM), FY26 Q2: -413.1% -413.1%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 40.4%
FY23 Q4 -5.9%
FY24 Q1 -16.8%
FY24 Q2 -69.7%
FY24 Q3 -162.2%
FY24 Q4 -232.8%
FY25 Q1 -211.5%
FY25 Q2 -206.7%
FY25 Q3 -224.9%
FY25 Q4 -248.7%
FY26 Q1 -325.8%
FY26 Q2 -413.1%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 0 3 0 1 40 19 11 14 10
Gross profit −0 — — — — — — — — — — — —
EBITDA −6 −10 −16 −7 −8 −4 −20 −23 18 −11 −62 −39 −51
Operating income −6 −10 −16 −7 −8 −4 −20 −23 18 −11 −62 −39 −51
Net income −3 −14 −11 −6 −9 −6 −25 −57 18 −10 −58 −50 −108
Diluted EPS −$0.05 −$0.18 −$1.20 −$0.60 −$0.70 −$2.17 −$5.28 −$3.82 $0.87 −$0.46 −$2.15 −$0.80 −$1.23
Growth (year on year)
Revenue — — — — — — −100.0% — +>999% −52.2% −42.3% +29.1% −36.1%
EBITDA — — — — — — — — — −157.9% — — —
Operating income — — — — — — — — — −158.0% — — —
Net income — — — — — — — — — −155.8% — — —
Diluted EPS — — — — — — — — — −152.9% — — —
Margins
EBITDA margin — — — — — −138.4% — <−999% 45.7% −55.4% −564.6% −271.5% −512.9%
Operating margin — — — — — −139.8% — <−999% 45.7% −55.5% −564.7% −271.9% −513.5%
Net margin — — — — — −205.6% — <−999% 44.9% −52.4% −523.4% −349.3% <−999%
Free-cash-flow margin — — — — — −120.6% — <−999% 35.9% −5.8% −232.7% −248.3% —
Cash flow
Cash from operations −5 −7 −16 −7 −8 −4 −7 −19 14 −1 −26 −35 −41
Capital spending — — — — — 0 0 0 0 0 0 0 —
Free cash flow — — — — — −4 −7 −19 14 −1 −26 −35 —
Stock-based pay 0 1 1 0 1 0 2 2 2 4 3 3 4
Free cash flow after stock pay — — — — — −4 −8 −21 13 −5 −29 −39 —
Balance sheet
Cash 7 12 10 13 19 2 16 25 43 51 30 45 89
Total debt 0 0 0 0 0 5 0 1 0 0 0 1 35
Net debt (negative = net cash) −7 −12 −10 −13 −19 3 −16 −24 −43 −51 −30 −44 −54
Diluted shares — — — — 1m 3m 5m 15m 21m 22m 27m 62m 87m
Returned to shareholders
Buybacks 0 0 0 — — — — — — — — — —
Total returned 0 0 0 — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 5 checks passed · June 30, 2026
What it owns · $93m
Short-term assets $93mLonger-term assets $0m
What it owes, and who funded it · $106m
Short-term liabilities $8mLonger-term liabilities $98mShareholders' equity $-13m
  • Short-term assets cover short-term liabilities $93m of assets due within a year against $8m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $93m short-term assets against $98m of longer-dated liabilities.
  • More cash than debt $89m of cash against $35m of debt.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt −$41m of operating cash flow against $35m of debt.
  • Operating profit covers interest at least five times over Operating income of −$51m against $272,000 of interest.

From Opus Genetics, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

Diluted share count
+127.5%
year over year
R&D spending
391.9%
of revenue
Days sales outstanding
39 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in biotechnology
Last 12 months unless stated IRD CRBU RLAY HYFT APLM SRZN Median
Revenue, last 12 months $10m $10m $10m $11m $9m $12m $56m
Revenue growth, last 12 months −36.1% 10.0% 23.9% 47.8% — −8.8% 12.6%
Revenue growth, 3-year average −39.8% −11.0% 122.3% — — — 13.7%
Revenue growth, latest quarter −73.8% −43.8% −48.3% — — 408.6% 10.2%
Operating margin −513.5% <−999% <−999% — — −385.3% −189.4%
Operating margin, 3-year average −341.9% <−999% <−999% — — — −363.5%
Net margin <−999% <−999% <−999% −89.7% −128.7% <−999% −169.8%
Cash from operations / revenue −412.6% −954.5% <−999% −80.1% −122.0% −302.0% −168.0%
Free-cash-flow margin −413.1% −954.2% <−999% −82.7% −122.0% −303.9% −162.4%
Free-cash-flow margin, 3-year average −229.8% −946.0% <−999% — — — −310.0%
Stock pay / revenue 45.3% 104.7% 466.8% 8.2% −11.5% 60.9% 20.0%
Change in share count 127.5% 4.7% 12.4% 38.9% 41.8% — 8.2%

Median of all 184 companies we cover in biotechnology. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

184 biotechnology companies
Measure Company Peer median Rank
Revenue growth Growth -36.1% 12.6% 136 of 172
Change in growth rate Growth -23.9pp -0.1pp 129 of 172
Operating margin Profitability -513.5% -189.4% 121 of 175
Net margin Profitability -1091.8% -157.3% 143 of 180
Free-cash-flow margin Cash generation -413.1% -145.4% 124 of 176
Stock pay as % of revenue Cash generation 45.3% 19.2% 112 of 179
Long-term debt as % of assets Balance sheet 37.9% 20.6% 61 of 78
Change in share count Balance sheet 127.5% 7.9% 153 of 156
Days sales outstanding Balance sheet 39 days 75 days 17 of 100

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$249M
Institutions reporting
103
Shares held vs prior quarter
▲ 33.4%
Positions opened / closed
40 / 16

Top buyers and sellers, Q2 2026: 73 institutions bought and 28 sold ; the biggest buyer was Nantahala Capital Management, LLC (+4.4M shares) and the biggest seller Perceptive Advisors LLC (−1.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Nantahala Capital Management, LLC $25.2M 6.1M 10.1% ▲ 264.2%
Caligan Partners LP $25M 6.1M 10.0% 0.0%
Adage Capital Partners Gp, L.L.C. $24.8M 6.0M 10.0% 0.0%
Bios Capital Management, LP $15.1M 3.7M 6.1% 0.0%
Blackrock, Inc. $12.8M 3.1M 5.1% ▲ 2009.4%
Balyasny Asset Management L.P. $12.7M 3.1M 5.1% ▲ 13.6%
Vanguard Capital Management LLC $12.2M 3.0M 4.9% ▲ 20.8%
Boxer Capital Management, LLC $11.6M 2.8M 4.6% ▲ 25.1%
Trails Edge Capital Partners, LP $11.3M 2.7M 4.5% ▲ 448.7%
Millennium Management LLC $9.5M 2.3M 3.8% ▼ 12.5%
Great Point Partners LLC $8.1M 2.0M 3.3% ▲ 507.4%
Marshall Wace, LLP $8M 1.9M 3.2% ▼ 15.9%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Opus Genetics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $323,890 2 trades by 1 insider, last 12 months Insider sales History → $19.6M 23 trades by 7 insiders · 1% under pre-set plans
Net ▼ $19.2M net selling
Insider Date Trade Shares Price Value
Magrath George Chief Executive Officer October 23, 2026 Sell 9,591 $3.58 $34,384
Gagnon Robert E. Chief Financial Officer October 23, 2026 Sell pre-set plan 14,000 $3.55 $49,650
Yerxa Benjamin R President October 23, 2026 Sell 25,520 $3.53 $90,129
Yerxa Benjamin R President October 23, 2026 Sell 7,669 $3.55 $27,236
Schachle Joseph K Chief Operating Officer October 23, 2026 Sell 4,767 $3.56 $16,994
Foundation Fighting Blindness Retinal Degeneration Fund Director September 30, 2026 Sell 556,000 $4.96 $2.8M
Gagnon Robert E. Chief Financial Officer September 3, 2026 Sell pre-set plan 28,000 $4.54 $127,120
Gagnon Robert E. Chief Financial Officer July 23, 2026 Sell 7,783 $2.95 $22,960
Magrath George Chief Executive Officer July 23, 2026 Sell 9,475 $2.95 $27,951
Schachle Joseph K Chief Operating Officer July 23, 2026 Sell 4,644 $2.94 $13,653
Yerxa Benjamin R President July 23, 2026 Sell 7,429 $2.97 $22,064
Foundation Fighting Blindness Retinal Degeneration Fund Director May 18, 2026 Sell 1,700,000 $4.35 $7.4M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around October 19, 2026 estimated from the company's past filing pattern, not announced

  • August 6, 2026
  • May 12, 2026
  • March 10, 2026
  • February 19, 2026
  • November 12, 2025
  • August 13, 2025

Recent SEC filings

Data status

When each part of this page on Opus Genetics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Opus Genetics, Inc. in brief

What does Opus Genetics, Inc. do?
Opus Genetics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Opus Genetics, Inc.'s stock ticker?
Opus Genetics, Inc. trades under the ticker IRD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Opus Genetics, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Opus Genetics, Inc. reported revenue of $9.9M, 36.1% lower than a year earlier, according to its SEC filings.
What is Opus Genetics, Inc.'s free cash flow?
Opus Genetics, Inc.'s free-cash-flow margin is -413.1% of revenue over the trailing twelve months, ranking 124 of the 176 biotechnology companies we cover.
Who are Opus Genetics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Nantahala Capital Management, LLC, Caligan Partners LP and Adage Capital Partners Gp, L.L.C. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Opus Genetics, Inc.'s market cap?
On November 2, 2026, Opus Genetics, Inc.'s market capitalisation was about $324M and net debt of -$53.5M. Market figures come from third-party market data and may be delayed.
Who are Opus Genetics, Inc.'s competitors?
In our Biotechnology peer group, the companies closest to Opus Genetics, Inc. are Caribou Biosciences, Inc., Relay Therapeutics, Inc., Mindwalk Holdings Corp., Apollomics Inc. and Surrozen, Inc. The side-by-side comparison below sets their revenue, margins and growth against Opus Genetics, Inc.'s.
Are insiders buying or selling Opus Genetics, Inc. stock?
Over the last 12 months, Opus Genetics, Inc.'s directors and officers reported 2 open-market purchases and 23 sales on Form 4. The insider trading page charts every trade.
When is Opus Genetics, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Opus Genetics, Inc. announces its own schedule.